Open AccessPrognostic significance of long noncoding RNA Z38 as a candidate biomarker in breast cancer
Author(s) -
Nie ZhenLin,
Wang YiShan,
Mei YanPing,
Lin Xin,
Zhang GuoXing,
Sun HuiLing,
Wang YiLian,
Xia YongXiang,
Wang ShuKui
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22193
Subject(s) - breast cancer , oncology , long non coding rna , biomarker , hazard ratio , nomogram , medicine , carcinogenesis , cancer , proportional hazards model , metastasis , stage (stratigraphy) , cancer research , rna , confidence interval , biology , gene , biochemistry , paleontology
Background Long noncoding RNA (lnc RNA ) Z38 has been shown to promote cell proliferation and tumorigenesis in breast cancer. However, expression pattern and prognostic value of lnc RNA Z38 in breast cancer patients remain elusive. Methods The expression levels of SPRY 4‐ IT 1 in 110 self‐paired specimens of breast cancer and adjacent normal breast tissues were measured by quantitative real‐time PCR ( qRT ‐ PCR ), and its correlation with overall survival of patients with breast cancer was further statistically analyzed. Results Compared with normal breast tissues, Z38 was upregulated in breast cancer tissues. Furthermore, of 110 breast cancer patients, high Z38 expression was significantly associated with tumor‐node‐metastasis stage and lymph node metastasis. Further analysis using the Cox regression model revealed that Z38 expression was an independent prognostic factor of overall survival in patients with breast cancer (hazard ratio=4.74, 95% confidence interval 2.41‐9.32). The nomogram presents a good prediction of the probability of overall survival of breast cancer patients (c‐index: 0.792), and its predictive efficiency was further confirmed by the calibration curve. Conclusion Our data highlighted the potential of lnc RNA Z38 as novel candidate biomarker to identify patients with breast cancer at high risk of tumor death.